These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36720497)

  • 1. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay.
    Raghav K; Overman M; Poage GM; Soifer HS; Schnabel CA; Varadhachary GR
    Oncologist; 2020 Nov; 25(11):e1807-e1811. PubMed ID: 32893931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.
    Rassy E; Boussios S; Pavlidis N
    Eur J Clin Invest; 2021 Sep; 51(9):e13583. PubMed ID: 33970501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
    Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
    Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immune profiling for cancer of unknown primary site.
    Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
    J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
    Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
    Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.
    Takamatsu S; Hamanishi J; Brown JB; Yamaguchi K; Yamanoi K; Murakami K; Gotoh O; Mori S; Mandai M; Matsumura N
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35868660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
    Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
    Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
    Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
    Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.
    Dalens L; Lecuelle J; Favier L; Fraisse C; Lagrange A; Kaderbhai C; Boidot R; Chevrier S; Mananet H; Derangère V; Truntzer C; Ghiringhelli F
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
    Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
    JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives.
    Hossain SM; Carpenter C; Eccles MR
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.